Skila Named Preferred Partner By Nycomed

Feb. 24, 2010 - PRLog -- Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, today announced a new and expanded Master Services Agreement (MSA) with Nycomed – a Zurich-based pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. In this agreement, Nycomed has recognized Skila as a preferred partner, and has expanded the availability of Skila’s comprehensive managed solution offerings to additional Nycomed users, business units and geographies.

The new 3-year agreement will continue to include Skila’s industry-leading global Key Opinion Leader (KOL) collaboration software and services currently used by Nycomed Headquarters and country affiliates to manage relationships with medical experts. Under the new agreement, more brand teams can effortlessly take advantage of these KOL Management capabilities. The agreement also includes world-wide access to additional capabilities focused on Market Access and Key Account Management, Global Product Launch Management, Competitive Intelligence, Alliance Management, and Business Performance Management.

“Using Skila's cutting edge technology and services, we are able to put all of our knowledge in one place to provide transparency for the entire organization,” says Ulf Jonson, Sr. International Brand Manager, Nycomed. “Skila has been named a preferred partner as a result of their ability to deliver on-going value and impact. Their industry leadership, a strong and flexible solution roadmap, and an on-going commitment to deliver value are essential to the success of Nycomed and the value we deliver to the patient and professional communities. Skila’s solutions are the backbone to internal and external knowledge and collaboration, helping us centralize and disseminate the knowledge we need to make the most of opportunities while reducing the challenges.”

“Delivering on-going value through the use of our software, methodology and services is key to our success as well as the success of our clients,” says Simon Mason, COO, Skila. “This partnership is a further testament to Skila’s value proposition of providing fully managed, integrated, and sustainable solutions to our clients. We understand our clients’ needs and are able to quickly deliver solutions that solve their issues or help them seize market opportunities. We pride ourselves on building long-lasting partner relationships with our clients, with a win-win for both.”


About Nycomed
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.  Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialized through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.4 billion in 2008 and an adjusted EBITDA of €1.2 billion. For more information visit www.nycomed.com

About Skila
Skila is a global technology and services company specializing in knowledge and effectiveness solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, market access, executive and alliance management teams. These solutions include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances.


Having developed strong relationships with a broad number of global Pharmaceutical companies, Skila’s solutions have been deployed in 61 countries, supporting numerous global brands and over 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the long-term growth and adoption of our methodology, technology and continuous services as the business platform of choice for many of our clients. To learn more about Skila visit our website at www.skila.com.

# # #

Skila is a global technology and services company specializing in knowledge and effectiveness solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, executive and alliance management teams.